CMAP-L-243

General Information


DRACP ID  DRACP01136

Peptide Name   CMAP-L-243

Sequence  KKKKFFMLVKKKKFF

Sequence Length  15

UniProt ID  Not available

PubChem CID  Not available

Origin  Not available

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MDA-MB-231 Breast adenocarcinoma Carcinoma At a concentration of 100μM, the 24 h cell viability is approximately 73%(Duncan-test,P<0.05) MTT assay 24 h Patent

Hemolytic Activity  Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM

Normal (non-cancerous) Cytotoxicity  Less toxic than CDDP on human normal MCF10A and 293FT

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01136

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C100H163N23O16S

Absent amino acids  ACDEGHINPQRSTWY

Common amino acids  K

Mass  222548

Pl  11.65

Basic residues  8

Acidic residues  0

Hydrophobic residues  6

Net charge  8

Boman Index  -2117

Hydrophobicity  -67.33

Aliphatic Index  45.33

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID CN106831946A

Patent Title  Anticancer peptide as well as preparation method and application thereof  

Other Iinformation  Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status: Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020

Other Published ID  CN106831946B 




DRACP is developed by Dr.Zheng's team.